[1] YAMAZAWA S, USHIKU T, SHINOZAKI-USHIKU A, et al.Gastric cancer with primitive enterocyte phenotype: an aggressive subgroup of intestinal-type adenocarcinoma[J]. Am J Surg Pathol, 2017, 41(7): 989-997.
[2] BEN-PORATH I, THOMSON M W, CAREY V J, et al.An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors[J]. Nat Genet, 2008, 40(5): 499-507.
[3] MATTIOLO P, SCARPA A, LUCHINI C.Hepatoid tumors of the gastrointestinal/pancreatobiliary district: morphology, immunohistochemistry, and molecular profiles[J]. Hum Pathol, 2023, 132: 169-175.
[4] HANINGER D M, KLOECKER G H, BOUSAMRA II M, et al.Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature[J]. Mod Pathol, 2014, 27(4): 535-542.
[5] USHIKU T, SHINOZAKI A, SHIBAHARA J, et al.SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma[J]. Am J Surg Pathol, 2010, 34(4): 533-540.
[6] CHUN J, MOORE M, KELLY P, et al.Enteroblastic cholangiocarcinoma: An uncommon, underrecognized subtype of bile duct cancer[J]. Hum Pathol, 2024, 144: 46-52.
[7] WANG Y, LIU Y Y, HAN G P.Hepatoid adenocarcinoma of the extrahepatic duct[J]. World J Gastroenterol, 2013, 19(22): 3524-3527.
[8] QIAN X, ZHOU D, GAO B, et al.An alpha-fetoprotein-negative hepatoid adenocarcinoma of the gallbladder with squamous differentiation[J]. Hepatobiliary Surg Nutr, 2020, 9(1): 116-118.
[9] OKURA K, ESAKI M, NARA S, et al.Hepatoid carcinoma and related entities of the extrahepatic bile duct: A clinicopathological study of four cases[J]. Pathol Int, 2022, 72(6): 332-342.
[10] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[11] GALLAGHER C, KHOR T S.Intermediate cell carcinoma of the liver[J]. Pathology, 2024, 56(1): 124-127.
[12] MALVI D, DE BIASE D, FITTIPALDI S, et al.Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediate-cell carcinoma?[J]. Histopathology, 2020, 76(2): 265-274.
[13] LIN J X, WANG Z K, HONG Q Q, et al.Assessment of clinicopathological characteristics and development of an individualized prognostic model for patients with hepatoid adenocarcinoma of the stomach[J]. JAMA Netw Open, 2021, 4(10): e2128217.
[14] LIU X, SHENG W, WANG Y.An analysis of clinicopathological features and prognosis by comparing hepatoid adenocarcinoma of the stomach with AFP-producing gastric cancer[J]. J Surg Oncol, 2012, 106(3): 299-303. |
